about
Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathwayHuman homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteinsActivity of Sorafenib against desmoid tumor/deep fibromatosisEpithelioid Sarcoma: Opportunities for Biology-Driven Targeted TherapyPrimary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorKDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitorsAnaplastic lymphoma kinase inhibition in non-small-cell lung cancer.Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.Treatment of soft tissue sarcoma: a focus on earlier stages.Monogenic and polygenic determinants of sarcoma risk: an international genetic study.Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.Bluish papule in a middle-aged man.Other targetable sarcomas.Preliminary results of high-dose single-fraction radiotherapy for the management of chordomas of the spine and sacrum.Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.Ifosfamide may be safely used in patients with end stage renal disease on hemodialysisIGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting.R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyCixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialEfficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trialEfficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplificationNew therapeutic targets in soft tissue sarcoma.Sarcoma.Patient-derived xenografts for individualized care in advanced sarcoma.Role of interleukin 12 and costimulators in T cell anergy in vivo.Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.Chemotherapy in clear cell sarcoma.Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.
P50
Q24298295-0A712837-DA56-48BD-9796-DC3C5AA58C9BQ24557556-B3CFF10E-B86B-4121-8A06-8FAA735F8EF5Q24620775-1748B291-CC01-4303-8221-40693A6FC625Q26782730-B5B83F65-A66B-4FE0-83C4-1B2A601A9EC9Q27851455-46703F9A-7114-4731-94F5-AD32874CEE75Q27851484-786A28DB-513F-4C0B-A30C-5C74BAA66498Q27851588-04830B2A-51FD-457A-9142-DCACCE83DD1EQ27851589-11DB49AF-9375-488B-94E4-FC1F503B0AA6Q30240235-B5CFD0BA-AC66-4831-95B1-4E024B3526CDQ32491318-980D391A-1A6C-47A3-B76B-A606BDA38F79Q33152333-B44ED4A4-1129-4185-98FE-EE71D6480D4AQ33272462-4DD591C0-C25C-4542-A5B4-BF389D8FC137Q33273478-8D321258-10A1-4B80-9F88-C218EEAC1626Q33274866-B5BFDF49-AC35-4844-9486-C678935CD239Q33342842-99DF86A6-A43A-4358-BF6D-D644F4F62309Q33349428-148D6B84-BFD4-4722-A3A8-E9301E1927F4Q33387990-35ECDDC4-4017-4D46-A958-D8936CEDB0BEQ33389954-50C73B53-57EB-44BF-B985-B5F5B1E35FA1Q33397796-A7A74DB1-CFD9-4795-98A6-0EFE22197223Q33406371-4550C5BD-748E-4E8A-B47B-DBD72A19EB47Q33442984-2740CC5D-2261-467C-A019-5EEC93961641Q33633409-AECE7BA9-4AED-4C4F-B486-F8A84B016113Q33699901-A281DCA1-4094-4122-8973-88BB0F8616F4Q34023544-0234C5FF-BE08-4ADD-9B3A-70F2B8356FBEQ34026081-06BBF25C-D5C9-4ADB-A98C-E145517965CAQ34181123-1518123A-85E2-4DB7-952D-20A71BBF0C2FQ34267924-98CA631B-9739-4A80-8206-7DA4ECE8A700Q34347726-41841716-FB6A-446F-9A9C-B0DB1A37CD06Q34413869-C50C26A1-D2FA-4280-81C1-0A533F28DAA1Q34440866-328029A3-36B9-4E8C-8470-9847A5167E3BQ34547132-283B5C5B-D510-48BF-B601-FAE23BD8CD86Q34580719-D7E1B8B1-E532-4D6A-84B0-DF843ADF3DB8Q34587751-394F0FAC-C233-46B4-B48C-9F2FCAD166F5Q34607838-B675A135-2D93-4896-BD64-689948912719Q34618708-2D0717B9-A475-49A1-9B5E-061203C57453Q34639555-9EA4AEEC-B151-4D7F-8ED2-A3C2A0D42975Q34639805-B7BB0878-AE64-4830-84CE-7C28418DC1ADQ34645665-801829B7-B1C6-45A3-BE80-30D680842C5DQ34647409-6638C9F5-7473-4C71-8E7F-57C7B726BDB6Q34736667-BE75DA54-870E-498A-BD3E-14CAA899C0DD
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Robert G Maki
@fr
Robert G. Maki
@en
Robert G. Maki
@es
Robert G. Maki
@nl
Robert G. Maki
@sl
type
label
Robert G Maki
@fr
Robert G. Maki
@en
Robert G. Maki
@es
Robert G. Maki
@nl
Robert G. Maki
@sl
prefLabel
Robert G Maki
@fr
Robert G. Maki
@en
Robert G. Maki
@es
Robert G. Maki
@nl
Robert G. Maki
@sl
P214
P244
P106
P1153
7101997786
P21
P214
P244
n2013182614
P31
P496
0000-0002-9853-2528
P735
P7859
lccn-n2013182614